Equities

Jiang Zhong Pharmaceutical Co Ltd

600750:SHH

Jiang Zhong Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)26.07
  • Today's Change0.23 / 0.89%
  • Shares traded4.77m
  • 1 Year change+4.83%
  • Beta--
Data delayed at least 15 minutes, as of May 31 2024.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Jiang Zhong Pharmaceutical Co Ltd is a China-based company mainly engaged in the pharmaceutical manufacturing industry. The Company's products are classified into over-the-counter drugs, prescription drugs, big health products and others, covering the fields of spleen and stomach, intestines, throat, tonic, rehabilitation nutrition, high-end tonic, cardiovascular and cerebrovascular, gynecology, urinary system and others OTC products include Jianweixiaoshi Tablets, Lactobacillus Tablets, Compound Coral Grass Tablets, and Bifidobacterium Triple Live Enteric Capsules. Health products mainly include peptides and protein powder products. Prescription drug products include Chinese medicine products such as Bazhen Yimu Capsules, Shenbao Capsules, Paishi Granules, Huangqi Shengmai Yin, Zhenju Jiangya Tablets, Shuangju Granules, Zhikang Tablets, Shuxiong Granules and others

  • Revenue in CNY (TTM)4.30bn
  • Net income in CNY734.24m
  • Incorporated1996
  • Employees4.01k
  • Location
    Jiang Zhong Pharmaceutical Co LtdNo. 788, Huoju Avenue, High-Tech ZoneNANCHANG 330096ChinaCHN
  • Phone+86 79 188169323
  • Fax+86 79 188162532
  • Websitehttps://www.jzjt.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
600750:SHH since
announced
Transaction
value
Jiangxi Jiangzhong Changrun Pharmaceutical Co LtdAnnounced25 Nov 202325 Nov 2023Announced21.82%830.00k
Jiangxi Jiangzhong Herbal Health Technology Co LtdAnnounced25 Nov 202325 Nov 2023Announced21.82%1.06m
Data delayed at least 15 minutes, as of May 31 2024.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Liaoning Cheng Da Co Ltd11.18bn17.48m15.11bn3.36k760.000.5182--1.350.0130.0137.3419.070.23584.416.493,330,121.00-0.53663.59-0.76445.2116.0314.15-2.289.890.7792--0.283415.93-25.97-10.97-80.95-21.267.04--
KPC Pharmaceuticals Inc7.65bn432.35m15.27bn5.05k35.042.82--2.000.57570.575710.207.150.80212.482.621,513,702.004.635.427.769.1343.1243.685.775.701.4653.930.168835.75-6.991.6416.055.79-21.3314.87
Shanghai Shyndec Pharmaceutical Co Ltd11.78bn843.91m15.33bn11.61k17.881.21--1.300.63940.63948.959.480.60693.086.611,014,487.005.754.858.508.1737.0943.009.487.031.82--0.105717.52-6.861.2910.21-0.3897-2.210.00
Dizal Jiangsu Pharmaceutical Co Ltd172.61m-1.09bn16.40bn581.00--23.54--95.00-2.67-2.670.4221.680.10080.32156.78297,086.40-63.79-46.02-82.62-52.9996.4157.53-632.90-2,081.541.74--0.4557----18.29-50.50--21.35--
Jiang Zhong Pharmaceutical Co Ltd4.30bn734.24m16.41bn4.01k22.363.98--3.811.171.176.836.550.66984.3413.621,071,799.0012.3510.8218.8215.0864.0165.0218.4418.171.47--0.006182.8813.0020.1218.408.5411.4740.99
Shandong Buchang Pharmaceuticals Co Ltd12.37bn-22.28m17.36bn8.31k--1.50--1.40-0.0202-0.020211.1810.460.56781.009.581,488,478.00-0.90133.26-1.304.7264.0574.71-1.594.850.53482.340.2522121.01-11.41-0.6219120.85-29.93-16.56-36.72
Data as of May 31 2024. Currency figures normalised to Jiang Zhong Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

13.23%Per cent of shares held by top holders
HolderShares% Held
GF Fund Management Co., Ltd.as of 30 Sep 202334.50m5.53%
China Investment Corp. (Investment Management)as of 30 Sep 202315.55m2.49%
Ping An Fund Management Co., Ltd.as of 30 Sep 20237.83m1.26%
Zhong Ou Asset Management Co., Ltdas of 31 Dec 20235.54m0.89%
First Seafront Fund Management Co., Ltd.as of 31 Dec 20234.50m0.72%
Lion Fund Management Co., Ltd.as of 31 Dec 20234.20m0.67%
China Universal Asset Management Co., Ltd.as of 31 Dec 20233.46m0.56%
China Southern Asset Management Co., Ltd.as of 30 Jun 20233.15m0.50%
Harvest Fund Management Co., Ltd.as of 31 Dec 20232.25m0.36%
The Vanguard Group, Inc.as of 09 May 20241.56m0.25%
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.